| Date Filed | Type | Description |
| 08/21/2023 |
15-12G
| Form 15-12G - Securities registration termination [Section 12(g)]: |
| 08/11/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 08/09/2023 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 0% stake in DICE THERAPEUTICS, INC. |
| 08/09/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 08/09/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 08/09/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 08/09/2023 |
POSASR
| Form POSASR - Post-effective Amendment to an automatic shelf registration statement: |
| 08/09/2023 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 08/09/2023 |
8-K
| Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Fa... |
| 08/09/2023 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 08/09/2023 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 08/09/2023 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/25/2023 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 07/25/2023 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 07/17/2023 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 07/17/2023 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 07/10/2023 |
SC 13G/A
| FMR LLC reports a 4.7% stake in DICE THERAPEUTICS INC |
| 06/30/2023 |
SC 14D9
| Form SC 14D9 - Solicitation, recommendation statements: |
| 06/30/2023 |
SC TO-T
| Form SC TO-T - Tender offer statement by Third Party: |
| 06/07/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...|
Docs:
|
"DICE THERAPEUTICS, INC. AMENDED AND RESTATED CERTIFICATE OF INCORPORATION DICE Therapeutics, Inc., a Delaware corporation, hereby certifies as follows: 1. The name of this corporation is “DICE Therapeutics, Inc.” The date of the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware was September 14, 2021 under the name DICE Therapeutics, Inc. 2. The Amended and Restated Certificate of Incorporation of this corporation attached hereto as Exhibit A, which is incorporated herein by this reference, and which restates, integrates and further amends the provisions of the Certificate of Incorporation of this corporation as previously amended and/or restated, has been duly adopted by this corporation’s Board of Directors and by the s..." |
|
| 05/11/2023 |
8-K
| Quarterly results|
Docs:
|
"DICE Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights • First patient dosed in global Phase 2b clinical trial of lead oral IL-17 inhibitor, DC-806, in moderate-to-severe psoriasis • Topline data from Phase 1 clinical trial of second oral IL-17 inhibitor, DC-853, in healthy volunteers expected in 2H 2023 • Strong financial position with $554.5 million in cash, cash equivalents and marketable securities, providing runway into 2026 and through multiple expected clinical milestones SOUTH SAN FRANCISCO, CA, May 11, 2023 – DICE Therapeutics, Inc. , a biopharmaceutical company leveraging its proprietary DELSCAPE technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology, today reported fi..." |
|
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/05/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/03/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/03/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 04/26/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/26/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/26/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/14/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 03/29/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 03/15/2023 |
S-3ASR
| Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers: |
| 03/15/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/15/2023 |
8-K
| Quarterly results |
|